RELUMINATE

Welcome to the Brand page for “RELUMINATE”, which is offered here for Prescription pharmaceutical preparations for the treatment of diseases mediated by an opioid receptor, major depressive disorder, chronic depression, severe unipolar recurrent major depressive episodes, dysthymic disorder, depressive neurosis and neurotic depression, melancholic depression, atypical depression, reactive depression, treatment resistant depression, seasonal affective disorder and pediatric depression, premenstrual syndrome, premenstrual dysphoric disorder, hot flashes, bipolar disorders or manic depression, bipolar i disorder, bipolar ii disorder and cyclothymic disorder, anxiety, post-traumatic stress disorder, obsessive compulsive disorder and borderline personality disorder;.

Its status is currently believed to be active. Its class is unavailable. “RELUMINATE” is believed to be currently owned by “ALKERMES PHARMA IRELAND LIMITED”.